<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Lancet Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Lancet Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The Lancet. Neurology</journal-title></journal-title-group><issn pub-type="ppub">1474-4422</issn><issn pub-type="epub">1474-4465</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10112836</article-id><article-id pub-id-type="pmcid-ver">PMC10112836.1</article-id><article-id pub-id-type="pmcaid">10112836</article-id><article-id pub-id-type="pmcaiid">10112836</article-id><article-id pub-id-type="manuscript-id">NIHMS1884395</article-id><article-id pub-id-type="pmid">36115364</article-id><article-id pub-id-type="doi">10.1016/S1474-4422(22)00188-0</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1884395</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1884395</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4511-201X</contrib-id><name name-style="western"><surname>Elafros</surname><given-names initials="MA">Melissa A</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9082-2694</contrib-id><name name-style="western"><surname>Andersen</surname><given-names initials="H">Henning</given-names><prefix>Prof</prefix></name><degrees>MD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7996-2696</contrib-id><name name-style="western"><surname>Bennett</surname><given-names initials="DL">David L</given-names><prefix>Prof</prefix></name><degrees>MBBS</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5575-2494</contrib-id><name name-style="western"><surname>Savelieff</surname><given-names initials="MG">Masha G.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Viswanathan</surname><given-names initials="V">Vijay</given-names><prefix>Prof</prefix></name><degrees>MD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8885-6748</contrib-id><name name-style="western"><surname>Callaghan</surname><given-names initials="BC">Brian C</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9162-2694</contrib-id><name name-style="western"><surname>Feldman</surname><given-names initials="EL">Eva L</given-names><prefix>Prof</prefix></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Neurology, University of Michigan, Ann Arbor, USA.</aff><aff id="A2"><label>2</label>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.</aff><aff id="A3"><label>3</label>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</aff><aff id="A4"><label>4</label>M.V. Hospital for Diabetes and Prof M Viswanathan Diabetes Research Centre, Royapuram, Chennai, India.</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Contributors</p><p id="P2">MAE contributed to conceptualization, writing, review, and editing. HA contributed to conceptualization, writing, review, and editing. MGS contributed to conceptualization, writing, review, and editing. VV contributed to conceptualization, writing, review, and editing. DLB contributed to conceptualization, writing, review, and editing. BCC contributed conceptualization, writing, review, and editing. ELF contributed to conceptualization, writing, review, and editing. ELF had final say in the decision to submit the manuscript for publication.</p></fn><corresp id="CR1">Correspondence to: Eva L Feldman MD, PhD, <email>efeldman@umich.edu</email>, Department of Neurology, Michigan Medicine, University of Michigan, 5017 Biomedical Research Sciences Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109, United States</corresp><fn fn-type="COI-statement" id="FN2"><p id="P43">Conflict of interest</p><p id="P44">MAE has nothing to disclose. HA has nothing to disclose. MGS has nothing to disclose. VV has nothing to disclose. DLB reports grants from AstraZeneca, grants from Lilly, grants from Diabetes UK, during the conduct of the study; DLB has acted as a consultant on behalf of Oxford Innovation for Amgen, Bristows, LatigoBio, GSK, Ionis, Lilly, Olipass, Orion, Regeneron and Theranexus over the last 2 years, outside the submitted work; in addition, DLB has a patent application &#8216;a method for the treatment or prevention of pain, or excessive neuronal activity, or epilepsy&#8217; Application No. 16/337,428 pending. BCC reports personal fees from Medical legal work, grants from Veterans Affairs, personal fees from DynaMed, grants and personal fees from American Academy of Neurology, personal fees from Vaccine Injury Compensation Program, outside the submitted work. ELF has nothing to disclose.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2022</year></pub-date><volume>21</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">433702</issue-id><fpage>922</fpage><lpage>936</lpage><pub-history><event event-type="nihms-submitted"><date><day>06</day><month>04</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-20 15:25:37.453"><day>20</day><month>04</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1884395.pdf"/><abstract id="ABS1"><title>Summary</title><p id="P3">Diabetic peripheral neuropathy (DPN) occurs in up to half of individuals with types 1 (T1D) and 2 diabetes (T2D). DPN is a distal-to-proximal loss of peripheral nerve function causing physical disability and possibly pain, lowering quality-of-life. Early diagnosis improves clinical outcomes, but lifetime prognosis remains poor. Hyperglycemia is a DPN risk factor and glycemic control slows DPN in T1D. However, it has modest or no benefit in individuals with T2D, likely due to the high prevalence of comorbidities, including the metabolic syndrome, an additional risk factor. DPN pathophysiology is complex but converges on a unifying theme of bioenergetic failure in peripheral nerves secondary to their unique anatomy. Current management focuses on controlling diabetes, the metabolic syndrome, and pain, but remains suboptimal. Thus, research is on-going to improve early diagnosis, identify specific molecular pathways to develop mechanism-based therapies, and investigate lifestyle interventions to improve clinical outcomes and disease prognosis.</p></abstract><kwd-group><kwd>Diabetic peripheral neuropathy</kwd><kwd>diagnosis</kwd><kwd>epidemiology</kwd><kwd>management</kwd><kwd>pain</kwd><kwd>pathophysiology</kwd><kwd>risk factors</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>